Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Gastrointestinal tumours, non-colorectal

2205 - A phase III trial of muparfostat (PI-88) as adjuvant therapy in patients with hepatitis virus related hepatocellular carcinoma (HV-HCC) after resection


11 Sep 2017


Gastrointestinal tumours, non-colorectal


Clinical Research;  Cancer in Special Situations;  Hepatobiliary Cancers


Annals of Oncology (2017) 28 (suppl_5): v209-v268. 10.1093/annonc/mdx369


P. Chen1, P. Lee2, K. Han3, J. Fan4, T.T. Cheung5, R. Hu6, S.W. Paik7, W. Lee8, G. Chau9, L. Jeng10, H.J. Wang11, J.Y. Choi12, C. Chen13, M. Cho14, M. Ho15, C. Wu16, K.S. Lee17, Y. Mao18, F. Hu19, K. Lai20

Author affiliations

  • 1 Graduate Institute Of Clinical Medicine And Department Of Medical Research, National Taiwan University and National Taiwan University Hospital, 100 - Taipei/TW
  • 2 Department Of Surgery, National Taiwan University Hospital, 100 - Taipei/TW
  • 3 Department Of Internal Medicine, Yonsei University College of Medicine, Seoul/KR
  • 4 Liver Cancer Institute, Zhongshan Hospital, Cancer Center, Institute of Biomedical Sciences, Fudan University, Shanghai/CN
  • 5 Department Of Surgery, Queen Mary Hospital and University of Hong Kong, Hong Kong/HK
  • 6 Department Of Surgery, College Of Medicine, National Taiwan University Hospital, 100 - Taipei/TW
  • 7 Department Of Gastroenterology, Samsung Medical Center, College of Medicine, Sungkyunkwan University, Seoul/KR
  • 8 Division Of Liver And Transplantation Surgery, Department Of General Surgery, Chang Gung Memorial Hospital Linkou Branch, College of Medicine, Chang Gung University, Taipei/TW
  • 9 Department Of General Surgery, Taipei Veterans General Hospital, Taipei/TW
  • 10 Organ Transplantation Center, China Medical University Hospital, Taichung/TW
  • 11 Department Of Surgery, College of Medicine, Ajou University, Seoul/KR
  • 12 Division Of Hepatology, Department Of Internal Medicine, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul/KR
  • 13 Liver Transplantation Center And Department Of Surgery, Chang Gung Memorial Hospital Kaohsiung Branch, College of Medicine, Chang Gung University, Kaohsiung/TW
  • 14 Department Of Gastroenterology, Pusan National University Yangsan Hospital, Pusan/KR
  • 15 Department Of Surgery, National Taiwan University Hospital, College of Medicine, National Taiwan University, 100 - Taipei/TW
  • 16 Department Of General Surgery, Taichung Veterans General Hospital, Taichung/TW
  • 17 Department Of Gastroenterology, Gangnam Severance Hospital, Seoul/KR
  • 18 Department Of Liver Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing/CN
  • 19 Graduate Institute Of Clinical Medicine, College of Medicine, National Taiwan University, Taipei/TW
  • 20 New Drug Development, Medigen Biotechnology Corporation, Taipei/TW


Abstract 2205


Muparfostat is an investigational new drug which deters tumor growth by blocking tumor angiogenesis and prevents tumor cells from spreading via heparanase inhibition. Previous phase II trial of muparfostat demonstrated good tolerability and favorable clinical response.


This international multicenter clinical trial was conducted in Asia-Pacific region (Taiwan, Korea, China, and Hong-Kong) from 2011. A total of 520 HV-HCC patients after surgical resection were randomized (1:1) to receive injection of either muparfostat (160 mg/day, 4-days-on/3-days-off, 3-weeks-on/1-week-off) or placebo for 52 weeks and followed up for 96 weeks. The primary endpoint was centrally assessed disease-free survival (DFS). Secondary endpoints included overall survival (OS), time to recurrence, and safety.


Baseline patient demographics and characteristics were balanced between the treatment and placebo arms. All subjects completed the 52-week treatment. After interim analysis in 2014, the trial was concluded in 2015. The final intention-to-treat analysis (N = 519) yielded a non-significant result (p > 0.05) on DFS, not reaching the primary end point. Nevertheless, per-protocol analysis (N = 423) revealed a possible positive protective effect in subgroup patients with microvascular invasion. Muparfostat showed a significant prolongation in the disease-free time after completion of the 1-year treatment (hazard ratio: 0.13, 95% CI: 0.017 - 0.991, p = 0.049). Muparfostat had a good safety profile. There were five clinically suspected cases of heparin-induced thrombocytopenia but only one was confirmed.


Despite the DFS was not improved in the overall treatment group, muparfostat could significantly prolong the DFS in the microvascular-invasion subgroup, comprising 40% of the trial population. The finding potentiated muparfostat as single therapy or in combination with other anti-cancer agents for future HCC adjuvant therapy trials.

Clinical trial identification


Legal entity responsible for the study

Medigen Biotechnology Corporation


Medigen Biotechnology Corporation


P-J. Chen: Honorarium from Medigen Biotechnology Corporation. K-L. Lai: Employee of Medigen Biotechnology Corporation. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.